Phosphoproteins, E.g., Phosvitin, Vitellogenin, Etc. Patents (Class 530/352)
  • Patent number: 10995119
    Abstract: The present invention provides a novel molecule that catalyzes a hydrolysis reaction and is different from enzyme proteins. The catalytic peptide according to the present invention is a catalytic peptide that catalyzes a hydrolysis reaction, including at least one peptide selected from the group consisting of the following peptides (A1) to (A4): (A1) a peptide consisting of Box A and at least one of an upstream region and a downstream region therefrom in a Tob/BTG protein; (A2) a peptide consisting of a partial region of the peptide (A1); (A3) a peptide that consists of an amino acid sequence obtained by deletion, substitution, addition, and/or insertion of one or more amino acids in an amino acid sequence of the peptide (A1) or (A2) and has hydrolysis activity; and (A4) a peptide consisting of an amino acid sequence with a sequence identity of at least 85% to the amino acid sequence of the peptide (A1) or (A2) and having hydrolysis activity.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 4, 2021
    Assignee: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION
    Inventors: Toshifumi Akizawa, Tadashi Yamamoto
  • Patent number: 10206887
    Abstract: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 19, 2019
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Viktor Peykov, Patrick Soon-Shiong
  • Patent number: 9822177
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 21, 2017
    Assignee: ZYMOGENETICS, INC
    Inventors: Anthony W. Siadak, Shirley A. Rene, Janine M. Bilsborough
  • Patent number: 8986936
    Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: March 24, 2015
    Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de Rouen
    Inventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
  • Patent number: 8946386
    Abstract: Purified immunocytes were analyzed for expression frequencies, and the NKIR gene expressed specifically in natural killer (NK) cells was successfully identified. The NKIR gene encodes a receptor. Agonists and antagonists for the receptor can be identified by using the receptor.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: February 3, 2015
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kouji Matsushima, Shinichi Hashimoto, Masayuki Tsuchiya, Yuichi Hirata, Kenji Yoshida, Kazuyuki Ojima
  • Publication number: 20150023979
    Abstract: The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7 protein is separated from the non-phosphorylated E7 protein by a step wherein the non-phosphorylated E7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated E7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated HPV protein E7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies.
    Type: Application
    Filed: September 6, 2012
    Publication date: January 22, 2015
    Applicant: VALDOSPAN GMBH
    Inventor: Christian Kuhne
  • Publication number: 20150018273
    Abstract: The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal.
    Type: Application
    Filed: August 10, 2012
    Publication date: January 15, 2015
    Applicant: FOLICUM AB
    Inventors: Jan Alenfall, Pontus Duner, Anna Hultgardh Nilsson
  • Patent number: 8921520
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: December 30, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Patent number: 8889838
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 18, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Publication number: 20140329991
    Abstract: The invention provides methods and apparatus for the selective isolation of phosphorylated and glycosylated proteins and their fragments. A lanthanide metal cation is used to precipitate proteins or protein fragments containing phospho groups and/or glyco groups. The sample preparation method can be used for many types of biological samples, including HeLa cells, food, and human cerebrospinal fluid. The proteins are isolated, recovered and ready for analysis by mass spectrometry or other analytical methods allowing detection limits down to the femtomole level. The method and apparatus are valuable tools in the field of protein analysis and diagnostics.
    Type: Application
    Filed: January 17, 2013
    Publication date: November 6, 2014
    Inventors: Matthias Rainer, Fabio Polato, Douglas T. Gjerde, Guenther Bonn
  • Patent number: 8859734
    Abstract: The embodiments of the invention relate to a method for the introduction of a labeling structure such as a fluorescent molecules or a Raman tags to a compound. Imidazole functionalized resins or polymers are used to selectively immobilize phosphocompounds without protecting the carboxylic groups. Relying on the pKa difference between amines and hydrazides and carrying out the reaction in a slightly acidic buffer, all of the amines are protected by protonation while the hydrazides react with the phosphate imidazolide to form a phosphoramidate bond.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: October 14, 2014
    Assignee: Intel Corporation
    Inventors: Handong Li, Narayan Sundararajan
  • Patent number: 8829160
    Abstract: An isolated antibody that has a specific binding affinity to a polypeptide comprising the amino acid sequence HTEGKP (SEQ ID NO: 2) phosphorylated at threonine is provided. The antibody may be used as biomarker for mitotic cells. A method for using the antibody in accordance with the invention comprises contacting a cell with the antibody and detecting antibody bound to the cell as an indicator of the cell being in the mitotic state. A reagent kit comprising the antibody is also provided.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: September 9, 2014
    Assignee: The Florida State University Research Foundation, Inc.
    Inventors: Myra Hurt, Raed Rizkallah
  • Publication number: 20140221296
    Abstract: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides.
    Type: Application
    Filed: June 11, 2012
    Publication date: August 7, 2014
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Jianping Wu, Bo Lei, Jiandong Ren
  • Publication number: 20140200330
    Abstract: The invention provides methods and apparatus for the selective isolation of phosphorylated and glycosylated proteins and their fragments. A lanthanide metal cation is used to precipitate proteins or protein fragments containing phospho groups and/or glyco groups. The sample preparation method can be used for many types of biological samples, including HeLa cells, food, and human cerebrospinal fluid. The proteins are isolated, recovered and ready for analysis by mass spectrometry or other analytical methods allowing detection limits down to the femtomole level. The method and apparatus are valuable tools in the field of protein analysis and diagnostics.
    Type: Application
    Filed: January 17, 2013
    Publication date: July 17, 2014
    Inventors: Matthias Rainer, Fabio Polato, Douglas T. Gjerde, Guenther Bonn
  • Patent number: 8772456
    Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 8, 2014
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
  • Publication number: 20140161731
    Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: WisTa Laboratories Ltd.
    Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
  • Publication number: 20140080736
    Abstract: Tumour marker proteins and their preparation from fluids from one or more cancer patients, wherein said fluids are those which collect in a body cavity or space which is naturally occurring or which is the result of cancer or medical intervention for cancer. The present application also relates to preparation of tumour marker proteins from excretions taken from patients with cancer. The tumour marker proteins are useful as immunoassay reagents in the detection of cancer-associated anti-tumour marker autoantibodies.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: Onclmmune Limited
    Inventors: John Forsyth Russell Robertson, Catherine Rosamund Louise Graves
  • Patent number: 8669074
    Abstract: A chimeric phosphorylation indicator (CPI) as provided herein can contain a donor molecule, a phosphorylatable domain, a phosphoaminoacid binding domain (PAABD), and an acceptor molecule. Where the phosphorylatable domain is phosphorylatable by protein kinase C (PKC), the CPI is a c-kinase activity reporter (CKAR). Donor and acceptor molecules may be, independently, fluorescent proteins such as non-oligomerizing fluorescent proteins. A CPI can contain a phosphorylatable polypeptide and a fluorescent protein; the phosphorylatable polypeptide may be contained within the sequence of the fluorescent protein, or the fluorescent protein may be contained within the sequence of the phosphorylatable polypeptide. The spatiotemporal properties of the PKC signal pathway may be tested with CKAR, calcium-sensing fluorophores and FRET-based translocation assays. Polynucleotides encoding such CPIs, and kits containing the indicators and/or the polynucleotides, are provided.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: March 11, 2014
    Assignee: The Regents of the University of California
    Inventors: Jonathan D. Violin, Alexandra C. Newton, Roger Y. Tsien, Jin Zhang
  • Patent number: 8669347
    Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 11, 2014
    Assignees: UCL Business PLC, Ludwig Instituted for Cancer Research
    Inventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
  • Publication number: 20140051831
    Abstract: The present invention pertains to a method for isolating osteopontin from a milk-derived feed containing caseino macropeptide and/or free beta casein, such as e.g. a feed based on milk serum or sweet whey. Particularly, the present method involves the use of a narrow window of pH and specific conductance of the milk-derived feed, which surprisingly has proven to provide a very efficient isolation of osteopontin from chemically complex feeds.
    Type: Application
    Filed: March 5, 2012
    Publication date: February 20, 2014
    Applicant: ARLA FOODS AMBA
    Inventors: Hans Bertelsen, Peter Langborg Wejse, Trine Trugvason
  • Publication number: 20130243755
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Application
    Filed: January 15, 2013
    Publication date: September 19, 2013
    Applicant: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventor: Institut National De La Santa Et De La Recherche Medicale (INSERM)
  • Patent number: 8518716
    Abstract: This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: August 27, 2013
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Carl A. Hubel, Janet M. Catov, Robin E. Gandley, James M. Roberts, Augustine Rajakumar
  • Publication number: 20130210037
    Abstract: The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR).
    Type: Application
    Filed: January 30, 2013
    Publication date: August 15, 2013
    Applicant: The Regents of the University of California
    Inventor: The Regents of the University of California
  • Patent number: 8507651
    Abstract: The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: August 13, 2013
    Assignee: DMI Acquisition Corp.
    Inventor: David Bar-Or
  • Patent number: 8501437
    Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 6, 2013
    Assignees: Trustees of Tufts College, The United States of America as Represented by the Secretary of the Air Force AFMCLO/JAZ, The Board of Trustees of The University of Illinois
    Inventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
  • Patent number: 8497353
    Abstract: Polypeptides which can be activated to cause the formation of pores in a lipid membrane are disclosed. Also disclosed are polypeptide compositions for the detection of target microorganisms and methods of using said compositions.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: July 30, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen B. Roscoe, Stephanie J. Moeller, Yi He, Richard B. Ross
  • Publication number: 20130109010
    Abstract: A novel means by which HCMV infection can be detected with a high sensitivity and whose practicality is high is disclosed. The present inventors synthesized as many as 15 kinds of HCMV proteins in their full length forms, and intensively studied their reactivities with sera from HCMV-infected patients to find that all the infected patients can be detected without fail when using the pp28 full length protein as an antigen. The pp28 full length protein can be synthesized and purified as a recombinant protein in a large scale by using Escherichia coli, and can be commercially used as an antigen for HCMV tests.
    Type: Application
    Filed: July 5, 2011
    Publication date: May 2, 2013
    Applicant: FUJIREBIO INC.
    Inventors: Nobuyuki Fujii, Hideo Honda, Yoshiaki Uchida, Kazuya Omi
  • Patent number: 8404458
    Abstract: The present invention relates to a method of modulating a chromatin binding protein or complex which binds to a functional group on an amino acid of a histone. This method involves phosphorylating or dephosphorylating a serine or threonine on the histone proximate to the amino acid under conditions effective to modulate the chromatin binding protein or complex. This method is particularly useful in treating or preventing cancer in a subject. In addition, the histone comprising a serine or threonine proximate to an amino acid capable of binding to a functional group can be used to screen for compounds which prevent or treat cancer. Also disclosed is an antibody or binding portion thereof raised against a binary switch on a histone comprising a phosphorylated serine or threonine proximate to an amino acid bound to a functional group and its use in detecting a condition mediated by that switch.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: March 26, 2013
    Assignee: The Rockefeller University
    Inventors: C. David Allis, Wolfgang Fischle, Holger Dormann
  • Publication number: 20130028914
    Abstract: Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies.
    Type: Application
    Filed: August 30, 2010
    Publication date: January 31, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventor: Rakez Kayed
  • Publication number: 20130019326
    Abstract: The invention provides methods and compositions for selectively promoting anti-metabolic disorder activity over classical PPAR gamma activation through modulation of PPAR gamma phosphorylation (e.g., Ser-273 phosphorylation of murine peroxisome proliferator activated receptor gamma (PPAR gamma) 2 or a corresponding serine residue in a murine PPAR gamma 2 homolog, including a human). Also provided are methods for preventing, treating, or predictiving responsiveness of therapies for metabolic disorders in a subject through selective inhibition of such PPAR gamma phosphorylation. Further provided are methods for identifying compounds that are capable of modulating such PPAR gamma phosphorylation.
    Type: Application
    Filed: January 20, 2011
    Publication date: January 17, 2013
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Jang Hyun Choi, Shingo Kajimura, Alexander Banks
  • Patent number: 8334368
    Abstract: A novel cytosolic 58 kd phosphoprotein induced during bone marrow stem cell (BM) differentiation into dendritic cells (DC) during in vitro cultivation with the cytokine GM-CSF by addition of antisera to an 82 kd BM cell surface protein generating cultivatable dendritic progenitor cells (DP). Genes, methods for preparing them as well as early DP have been provided. Potential uses/advantages lie in the study of BM differentiation and innate immunity due to stimulatory/inhibitory DC, contribution of BM and DP to inflammation during infection and carcinogenesis, tumor promotion/regression, identification of BM-derived blood cells, T-cell activation/regulation/tolerance and inflammation.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: December 18, 2012
    Inventor: Swapan K. Ghosh
  • Patent number: 8304521
    Abstract: Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS).
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 6, 2012
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Andrew D. Hollenbach, Patrick J. Miller, Kevin N. Dietz
  • Publication number: 20120225047
    Abstract: The present invention discloses genes, SNP markers and haplotypes of susceptibility or predisposition to obesity, type 2 diabetes (T2D) and subdiagnosis of obesity and T2D and related medical conditions. Particularly, the present invention provides T2D and obesity associated markers from gene SUCLA2. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes and other related biomarkers are also disclosed. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of obesity and T2D.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 6, 2012
    Inventor: Jukka T. Salonen
  • Patent number: 8207301
    Abstract: Provided are: a method of assessing hepatocellular carcinoma by using a protein with a different phosphorylated state in hepatocellular carcinoma cells compared with non-hepatocellular carcinoma cells; and a hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma formed of the protein. The hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma includes tumor rejection antigen gp96 formed of the amino acid represented by SEQ ID NO: 1, and is measured for its phosphorylated state to detect the presence or absence of hepatocellular carcinoma.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: June 26, 2012
    Assignee: NEC Corporation
    Inventors: Hirotaka Minagawa, Kenji Miyazaki, Yo Tabuse, Kenichi Kamijo, Shuichi Kaneko
  • Publication number: 20120142897
    Abstract: Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.
    Type: Application
    Filed: June 17, 2010
    Publication date: June 7, 2012
    Applicants: UNIVERSITE D'ORLEANS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Luigi A. Agrofoglio, Vincent Roy, Ugo Pradere
  • Publication number: 20120123088
    Abstract: The present invention relates to the use and to a process involving at least one calix[n]arene derivative substituted by at least one acid functional group on the upper face and at least one aliphatic chain of variable length on the other face, as an additive for crystallization of a polar and/or positively charged molecule. The use and the process of the present invention have the advantage of enabling, facilitating and/or accelerating the crystallization of polar and/or positively charged molecules, especially of membrane proteins that are in solution or soluble, which had previously proved to be very difficult.
    Type: Application
    Filed: April 2, 2010
    Publication date: May 17, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Pierre G. Falson, Anthony W. Coleman, Rachel Rima Matar Merheb, Antoine Leydier, Frederic Huche
  • Publication number: 20120082684
    Abstract: The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders.
    Type: Application
    Filed: March 15, 2010
    Publication date: April 5, 2012
    Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
    Inventors: Sonia Rocha, Angus Iain Lamond, Motoharu Ono, Kayo Yamada
  • Publication number: 20120022230
    Abstract: Relative quantification of metabolites by Electrospray Ionization Mass Spectrometry (ESI-MS) requiring a mechanism for simultaneous analysis of multiple analytes in two or more samples. Labeling reagents that are reactive to particular compound classes and differ only in their isotopic compositions facilitate relative quantification. Heavy and light isotopic forms of methylacetimidate were synthesized and used as labeling reagents for quantification of amine-containing molecules. Heavy and light isotopic forms of formaldehyde and cholamine were also synthesized and used independently as labeling reagents for quantification of amine-containing and carboxylic acid-containing molecules, such as found in biological samples. The labeled end-products are positively charged under normal acidic conditions involving conventional Liquid Chromatography Mass Spectrometry (LC/MS) applications.
    Type: Application
    Filed: June 8, 2011
    Publication date: January 26, 2012
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Lloyd M. SMITH, MICHAEL R. SHORTREED, BRIAN L. FREY, MARGARET F. PHILLIPS, JOSHUA J. COON, SHANE M. LAMOS, CASEY J. KRUSEMARK, PETER J. BELSHAW, MADHUSUDAN PATEL, NEIL L. KELLEHER
  • Publication number: 20120021432
    Abstract: The present invention relates to isolated phosphorylated NF45 peptides and isolated phosphorylation site-specific antibody or antigen-binding portion thereof that specifically binds a phosphorylated NF45 protein. The present invention also relates to methods of utilizing these antibodies to determine the therapeutic efficacy of a candidate compound and methods for screening for candidate compounds that increase the phosphorylation of NF45 protein in a cell.
    Type: Application
    Filed: April 15, 2011
    Publication date: January 26, 2012
    Applicant: ArQule, Inc.
    Inventors: Yi Yu, Xiubin Gu, Xiaolan Zhao, Carol Waghorne, Thomas C.K. Chan, Taiping Chen
  • Publication number: 20110312877
    Abstract: Biomedical nanoparticles are disclosed based on new engineered modular carrier macromolecules, on engineered macromolecules or associated entities providing an internal nanoparticle structure, and compositions for minimizing non-specific binding of the nanoparticles while enabling efficient and convenient targeting to cells and tissues. These nanoparticles may be used to deliver atomic or molecular or associated entities which are useful for diagnostics, primarily in vivo imaging, for therapeutics, for vaccines, or for experimental research. Nanoparticles comprising combinations of active entities such as gene inhibitors with gene expression cassettes or imaging agents with therapeutic agents, and polyamide compounds useful for treatment of microbial infections are also disclosed.
    Type: Application
    Filed: February 26, 2009
    Publication date: December 22, 2011
    Applicant: APARNA BIOSCEIENCES
    Inventors: Mark Berninger, Puthupparampil Scaria, Martin Woodle
  • Patent number: 8071721
    Abstract: The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: December 6, 2011
    Assignees: Ribovax Biotechnologies S.A., Bioline Diagnostici SRL
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Publication number: 20110293593
    Abstract: The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions.
    Type: Application
    Filed: February 11, 2009
    Publication date: December 1, 2011
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: David Wallach, Parameswaran Ramakrishnan, Andrei Kovalenko
  • Publication number: 20110230425
    Abstract: Compositions and methods for protecting and administering small RNA to preserve stability are described. The small RNAs may either be in unmodified form or may be chemically modified to enhance stability further.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 22, 2011
    Applicant: Institute For Systems Biology
    Inventors: Kai WANG, David Galas
  • Patent number: 7982008
    Abstract: The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: July 19, 2011
    Inventor: David Bar-Or
  • Publication number: 20110152122
    Abstract: The invention includes compositions comprising a S. cerevisiae yeast library, and methods of identifying an epigenetic marker for the diagnosis of infertility or a disorder associated with gametogenesis in an individual.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 23, 2011
    Inventors: Shelley L. Berger, Jerome Govin
  • Patent number: 7960509
    Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein domain used. The composites can also be loaded with other compounds (e.g. dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the materials or during the mineralization step in materials formation.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: June 14, 2011
    Assignees: The United States of America as represented by the Secretary of the Air Force AFMCLO/JAZ
    Inventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
  • Publication number: 20110117206
    Abstract: The present application relates to methods of providing thermodynamically stable calcium phosphate nanoclusters and uses thereof.
    Type: Application
    Filed: July 16, 2009
    Publication date: May 19, 2011
    Applicant: PLANT BIOSCIENCE LIMITED
    Inventors: Carl Holt, Roger Clegg
  • Publication number: 20110070663
    Abstract: The present invention relates to a method for the purification and isolation of phosphorylated and glycosylated analytes using titanium dioxide particles.
    Type: Application
    Filed: April 30, 2009
    Publication date: March 24, 2011
    Inventors: Joerg Von Hagen, Uwe Michelsen
  • Publication number: 20100331524
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 30, 2010
    Applicant: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Publication number: 20100303824
    Abstract: The invention provides a novel human protein, FISH adaptor protein, involved in amyloid ?-protein-mediated cell death. Also provided are methods for modulating amyloid ?-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein.
    Type: Application
    Filed: January 26, 2010
    Publication date: December 2, 2010
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: NIKOLAY MALININ, MAILE SKOMP, SARAH WRIGHT, IRENE GRISWOLD-PRENNER